Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 4,423 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression Diagnosis Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

TMS for Adults With Autism and Depression

NCT02939560
View directory record Official record
Conditions
Autism Spectrum Disorder, Depression, Depressive Disorder, Major Depressive Disorder
Interventions
NeuroStar® TMS device (Neuronetics, Atlanta, GA)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment

NCT01372254
View directory record Official record
Conditions
Cigarette Smoking, Drug Use
Interventions
Standard Treatment, BAD-AS, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

NCT00775203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Trazodone Hydrochloride (HCl) Extended-Release Tablets, Placebo
Drug
Lead sponsor
Labopharm Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 3, 2026, 6:56 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion

NCT07639827
View directory record Official record
Conditions
Wellness, Self Compassion, Burnout, Anxiety, Depression
Interventions
App-based bundled mental fitness intervention, App-based wellness module collection
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

NCT00227942
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Estrogen Replacement Therapy, Zolpidem, placebo
Drug
Lead sponsor
Hadine Joffe, MD
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 3, 2026, 6:56 PM EDT
Active, not recruiting Phase 3 Interventional

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

NCT06564818
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychological Support, Placebo
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

NCT00671515
View directory record Official record
Conditions
Depressive Disorder, Major, Metabolic Syndrome X
Interventions
Pioglitazone
Drug
Lead sponsor
Joseph Calabrese, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

An Expert System to Reduce Depression in Primary Care

NCT00497874
View directory record Official record
Conditions
Depression, Depressive Disorder, Major
Interventions
Computer-tailored intervention
Behavioral
Lead sponsor
Pro-Change Behavior Systems
Other
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

The Antidepressant Efficacy of the Anticholinergic Scopolamine

NCT00369915
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Scopolamine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 3, 2026, 6:56 PM EDT
Not yet recruiting No phase listed Observational

Validate the Temporal Stability and Responsiveness of AI-COA® for Depression and Anxiety

NCT07279025
View directory record Official record
Conditions
Depression Disorders, Anxiety Disorders
Interventions
Not listed
Lead sponsor
Deliberate Solutions Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Study to Treat Major Depressive Disorder With a New Medication

NCT03043560
View directory record Official record
Conditions
Depressive Disorder, Anhedonia
Interventions
Ezogabine, Placebos
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 3 Interventional

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

NCT00158990
View directory record Official record
Conditions
Major Depression, Bipolar Disorder, Unipolar Depression
Interventions
triiodothyronine, sertraline
Drug
Lead sponsor
Hadassah Medical Organization
Other
Eligibility
18 Years to 70 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2007 · Synced Oct 3, 2026, 6:56 PM EDT
Enrolling by invitation Phase 3 Interventional

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

NCT07217860
View directory record Official record
Conditions
Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
Interventions
Azetukalner
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 4 Interventional

Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse

NCT00223197
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Substance Abuse
Interventions
Pregnenolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

NCT00006517
View directory record Official record
Conditions
Seasonal Affective Disorder, Mood Disorders, Depression
Interventions
bright light box, dawn simulator, high-output negative ion generator, low-output negative ion generator, dawn light pulse
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Storytelling and Mindfulness for Graduate Student Wellbeing

NCT05826860
View directory record Official record
Conditions
Depression, Anxiety, Burnout, Student
Interventions
Mindfulness Practice, Storytelling Workshop
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pupillary Unrest as an Indicator of Central Opioid Effect in Subjects 40-60 Years of Age

NCT05391555
View directory record Official record
Conditions
Opioid Toxicity, Pupillary Miosis, Respiratory Depression
Interventions
Remifentanil Hydrochloride, Pupillometry measurement
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting Not applicable Interventional

Treatment of Depression Post-SCI

NCT04263285
View directory record Official record
Conditions
Depression, Spinal Cord Injuries
Interventions
rTMS
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

NCT06419608
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
62
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Recruiting Not applicable Interventional

Personalized Mobile Cognitive Behavioral Therapy Application

NCT05699525
View directory record Official record
Conditions
Anxiety Disorders and Symptoms, Depression, Bipolar Disorder, Symptoms
Interventions
Personalized MAYA Mobile App, General MAYA Mobile App
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 3, 2026, 6:56 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

NCT05169710
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Huntsville, Alabama • Bryant, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 3, 2026, 6:56 PM EDT
Completed Phase 4 Interventional

Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania

NCT00294255
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 3, 2026, 6:56 PM EDT
Withdrawn Not applicable Interventional

Videoconferencing Acceptance and Commitment Therapy With a Web App Use for Family Caregivers of People With Dementia

NCT05518968
View directory record Official record
Conditions
Depression
Interventions
Acceptance and commitment therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 3, 2026, 6:56 PM EDT